Editas Medicine reports positive EDIT-301 data; two SCD patients reach normal hemoglobin

Editas Medicine, Inc.

Patient 1 (SCD) total hemoglobin 16.4 g/dL at 5 months, maintained at 10-month follow-up; fetal Hb 45.4%.
Patient 2 (SCD) total hemoglobin 12.7 g/dL at 5 months, fetal Hb 51.3% at 6-month follow-up.
All four RUBY patients free of vaso-occlusive events post-infusion; no serious adverse events from EDIT-301.
First EdiTHAL beta thalassemia patient achieved 34.9% fetal Hb (4 g/dL total Hb) at 1.5 months.
Company on track to dose 20 RUBY patients by year-end; data presented at EHA Congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.